Japanese Researchers Create Cancer-Specific Immune Cells

A team of Japanese researchers revealed that they have managed to develop cancer specific immune system cells, known as T lymphocytes, from induced pluripotent stem cells (iPS cells).

To create these killer cells, the team from the RIKEN Research Centre for Allergy and Immunology first had to reprogram T lymphocytes specialized in killing a certain type of cancer, into iPS cells.

Tumor Markers - For Cancer Diagnosis and Prognosis
An ideal tumor marker for a cancer should be specific to that cancer and not generate false positive results.

The iPS cells then generated fully active, cancer-specific T lymphocytes. These lymphocytes regenerated from iPS cells could potentially serve as cancer therapy in the future.

Previous research has shown that killer T lymphocytes produced in the lab using conventional methods are inefficient in killing cancer cells mainly because they have a very short life-span, which limits their use as treatment for cancer.

To overcome these problems, the Japanese researchers led by Hiroshi Kawamoto reprogrammed mature human killer T lymphocytes into iPS cells and investigated how these cells differentiate.

Carcinoid Tumors - Carcinoid Syndrome - Symptoms, Signs, Diagnosis & Treatment
Carcinoid tumors is a benign tumor that results in carcinoid syndrome. Only 8 to 10% of all carcinoid tumors are associated with the carcinoid syndrome.

The team induced killer T lymphocytes specific for a certain type of skin cancer to reprogram into iPS cells by exposing the lymphocytes to the 'Yamanaka factors'.

The 'Yamanaka factors' is a group of compounds that induce cells to revert back to a non-specialized, pluripotent stage. The iPS cells obtained were then grown in the lab and induced to differentiate into killer T lymphocytes again.

About Brain Tumor
Brain tumors are the abnormal growth of brain cells that may be benign or metastatic. Brain tumors account for about 2.4% of all the tumor diagnosesandare most challenging due to their critically delicate location.

This new batch of T lymphocytes was shown to be specific for the same type of skin cancer as the original lymphocytes: they maintained the genetic reorganization enabling them to express the cancer-specific receptor on their surface. The new T lymphocytes were also shown to be active and to produce the anti-tumour compound interferon.

"We have succeeded in the expansion of antigen-specific T cells by making iPS cells and differentiating them back into functional T cells. The next step will be to test whether these T cells can selectively kill tumour cells but not other cells in the body. If they do, these cells might be directly injected into patients for therapy. This could be realized in the not-so-distant future." Dr Kawamoto said.

The study has been recently published online in the journal Cell Stem Cell.

Source-ANI